Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation Therapy for AML Guided by LSC Behavior
NCT01588951Phase 3Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2013
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cytarabine in acute myeloid leukemia (AML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Dec 2013; status: terminated.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01588951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01588951.